Pharmaceutical News

RSS

Neurologix third quarter net loss decreases to $2.3 million

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system ("CNS"), today reported its financial results for the three and nine months ended September 30, 2010.

12 Nov 2010

Labopharm receives notice of Activis' ANDA submission for generic OLEPTRO

Labopharm Inc. today announced that on November 11, 2010 it received notice from Actavis South Atlantic LLC advising that Actavis has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for approval to market 150 and 300 mg generic versions of OLEPTRO™ (trazodone hydrochloride extended-release 150 and 300 mg tablets) in the United States.

12 Nov 2010

VIMOVO granted marketing and pricing approval in the UK

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has been notified by AstraZeneca that marketing and pricing approval for VIMOVO™ (naproxen/ esomeprazole magnesium) 500/20 mg modified-release tablets, has been granted in the United Kingdom (UK).

12 Nov 2010

Dreaded cod liver oil in a variety of flavours

The stomachs of the generation of 50 year olds and above, will be churning at the thought of their parents and grandparents serving up spoonfuls of the much dreaded cod liver oil. As a practice, parents giving their children cod liver oil has all but died, and yet, as a population, we have seen more and more inflammatory conditions effect people's lives, which are due in no small part to the 'modern day diet', which many of us live.

12 Nov 2010

Drug industry roundup: Fosamax trial focuses scrutiny on osteoporosis drugs; What about $4 generics; Recalls undermining confidence

The New York Times: A civil trial against the drugmaker Merck is now underway in Manhattan. A retired investigator for the U.S. army is one of 1,400 people suing the company on the premise that Fosamax, a Merck drug used by millions of women with thinning bones, caused them to develop jawbone ailments.

12 Nov 2010

Urgent action needed to prevent and treat childhood pneumonia

A Pneumonia Report Card released today by the International Vaccine Access Center (IVAC) on behalf of the Global Coalition against Child Pneumonia reveals where urgent efforts are needed to reach target levels of coverage for the life-saving interventions that can prevent, protect against and treat pneumonia in children.

12 Nov 2010

Ordway, Milestone to develop drug formulation for administration through CompuFlo injection technology

Milestone Scientific Inc., the recognized leader in advanced, computer controlled drug delivery technologies, and Ordway Research Institute, a leading research and drug development organization, have agreed to develop drug formulations for precise targeted delivery of drugs to affected body parts, organs and cancerous tissue through Milestone's patented CompuFlo injection technology.

12 Nov 2010

Carter Center, Merck take steps to prevent river blindness in Latin America

Public health officials at the 20th Inter-American Conference on Onchocerciasis in Antigua, Guatemala, confirmed that more than one-third of all Latin Americans who ran the risk of contracting river blindness (onchocerciasis), a leading cause of preventable blindness, are no longer at risk.

12 Nov 2010

Oligomerix receives SBIR Phase II grant to develop drugs for Alzheimer’s disease

Oligomerix, Inc. today announced the receipt of a two-year Small Business Innovation Research (SBIR) Phase II grant for $1.6M from the National Institute on Aging, National Institutes of Health (NIH), for a program to discover small molecules and antibodies targeting tau protein oligomers in the development of disease modifying therapeutics for Alzheimer's disease.

12 Nov 2010

Forest enters commercialization collaboration with Janssen for Bystolic and Savella in Canada

Forest Laboratories, Inc. announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic® (nebivolol) and Savella® (milnacipran HCl) in Canada with Janssen Pharmaceutica, NV and Janssen Pharmaceutical respectively, on behalf of Janssen Inc., which will market the products in Canada.

12 Nov 2010

Diabetic drug may retard growth of fluid-filled cysts in PKD: Research

Researchers report that a drug commonly used to treat diabetes may also retard the growth of fluid-filled cysts of the most common genetic disorder, polycystic kidney disease.

12 Nov 2010

Aeras receives grant to develop new vaccines for TB

The Aeras Global TB Vaccine Foundation is pleased to announce that the Netherlands Ministry of Foreign Affairs has renewed its funding to Aeras with a pledge of an additional 11.7 million over four years (2011-2014) to further its efforts to develop new vaccines to help combat the global epidemic of tuberculosis.

12 Nov 2010

COMP issues positive opinion for Celsion's ThermoDox Orphan Drug Designation

Celsion Corporation, a leading oncology drug development company, today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on the application for Orphan Drug Designation for ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, for the treatment of hepatocellular carcinoma (HCC), commonly referred to as primary liver cancer.

12 Nov 2010

Nature News examines meningitis vaccine program to roll out in Africa

Nature News reports on an immunization campaign kicking off in Africa in December that will offer protection to some areas of Africa's meningitis belt. Millions will receive a new vaccine, MenAfriVac, that promises protection against the meningococcal bacterium Neisseria meningitides, the news service writes, noting the effort is the culmination of ten years' work by an international consortium to develop a vaccine at a price low enough for massive use in Africa: just US$0.40 a dose.

12 Nov 2010

FDA grants SEDASYS System appeal

Ethicon Endo-Surgery, Inc. (EES) today announced that the Commissioner's Office of the U.S. Food and Drug Administration (FDA) has granted the appeal of the Center for Devices and Radiological Health's (CDRH) denial of the SEDASYS System Premarket Approval Application (PMA). As a result, a new Independent Advisory Panel will be appointed to reconsider the SEDASYS System clinical trial data and application.

11 Nov 2010

Meda acquires Pyralvex, Spasmonal and Waxsol from Norgine

Meda has acquired three well established OTC products from Norgine, a Dutch pharma company. The products are Pyralvex (relief of pain associated with e.g. aphthous ulcers), Spasmonal (treatment of for example Irritable Bowel Syndrome) and Waxsol (ear drops). The largest product is Pyralvex, which has a turnover of about 90 MSEK.

11 Nov 2010

FDA identifies promising steps to enhance safety of CT scans

The U.S. Food and Drug Administration has been investigating reports that patients undergoing computed tomography (CT) brain perfusion scans were accidently exposed to excess radiation. The FDA found that when properly used, the CT scanners did not malfunction. Instead, it is likely that the improper use of the scanners resulted in these overdoses. However, the FDA has identified a series or promising steps to enhance the safety of these procedures. These steps could reduce the likelihood of radiation overexposure in the event of improper use of the CT scanners.

11 Nov 2010

Most drug and biological product makers meet postmarketing requirements and commitments

Most makers of approved drug and biological products are meeting their regulatory obligations and meeting targets for postmarketing studies/clinical trials in a timely manner, according to a study released today by the U.S. Food and Drug Administration (FDA).

11 Nov 2010

Adolor receives U.S. Patent for beloxepin to treat pain

Adolor Corporation today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,829,576 covering the use of ADL6906 (beloxepin), a small molecule, for the treatment of pain. The issued patent will expire on February 19, 2029.

11 Nov 2010

New 'magic bullet' can eradicate side effects of drug used to treat cystinosis

A 'magic bullet' designed by pharmaceutical scientists at an English university could eradicate the side effects of a drug used to treat a rare genetic disease. Researchers at the University of Sunderland have chemically modified a drug used to treat cystinosis a disease which occurs when the body's mechanism to remove excess cystine (an amino acid) breaks down, leading to kidney problems and eventually affecting other organs to remove unpleasant side effects such as nausea, vomiting, severe halitosis, body odour and a noxious taste.

11 Nov 2010